Chief scientific officer at Johnson & Johnson set to retire this year

As with Johnson & Johnson's CEO Alex Gorsky, the company's Chief Scientific Officer Paul Stoffels wants to step aside at the New Year, leaving the post for an as-of-yet unknown replacement.

Photo: Janssen/PR

Paul Stoffels, chief scientific officer at Johnson & Johnson, will exit his role at the company effective from the end of 2021, reports Bloomberg News.

The pharmaceutical giant has yet to find a replacement for Paul Stoffels, who has been with the company since 2002, spearheading the development of many treatments for HIV, Ebola and Zika virus, for example.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Further reading

Related articles

Trial banner

Latest news

See all jobs